The report provides an overview of the global peripheral blood mononuclear cells (PBMCs) market and analyzes market trends. It includes global revenue ($ Thousand) using 2025 as the base year, estimated data for 2026, and projected data for 2026 through 2031.
The report segments the market by product type, application, and technology. By product type, the market is segmented into cryopreserved or frozen PBMCs, peripheral blood mononuclear cell isolation and viability kits, cultured or fresh PBMCs, and others. Based on application, the market is categorized into oncology, immunology, vaccine development, toxicology, infectious disease, and others. By technology, the market is segmented into density gradient centrifugation, leukapheresis, and others. Geographical regions covered in this study include North America (the U.S., Canada, and Mexico), Europe (Germany, the U.K., Italy, France, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia-Pacific), South America, and the Middle East and Africa (MEA) with a focus on the major countries in these regions.
The report focuses on the key drivers, trends, and challenges shaping the market and vendor landscape. It analyzes and discusses emerging technologies related to the market.
The report concludes with an analysis of the competitive landscape and highlights the leading global peripheral blood mononuclear cell companies. It also includes a dedicated section of company profiles covering company overviews, key financials, product portfolios, and recent developments.
The report segments the market by product type, application, and technology. By product type, the market is segmented into cryopreserved or frozen PBMCs, peripheral blood mononuclear cell isolation and viability kits, cultured or fresh PBMCs, and others. Based on application, the market is categorized into oncology, immunology, vaccine development, toxicology, infectious disease, and others. By technology, the market is segmented into density gradient centrifugation, leukapheresis, and others. Geographical regions covered in this study include North America (the U.S., Canada, and Mexico), Europe (Germany, the U.K., Italy, France, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia-Pacific), South America, and the Middle East and Africa (MEA) with a focus on the major countries in these regions.
The report focuses on the key drivers, trends, and challenges shaping the market and vendor landscape. It analyzes and discusses emerging technologies related to the market.
The report concludes with an analysis of the competitive landscape and highlights the leading global peripheral blood mononuclear cell companies. It also includes a dedicated section of company profiles covering company overviews, key financials, product portfolios, and recent developments.
The report includes:
- 40 data tables and 54 additional tables
- Examination of the global peripheral blood mononuclear cells (PBMCs) market, covering research applications, technological developments, and the growing role of immune cell analysis in life sciences and clinical research
- Market estimates based on 2025 data, with revenue forecasts and growth projections for the period from 2026 through 2031
- Analysis of market segments by product type, application, and isolation technique,
- Discussion of key market drivers, restraints, opportunities, and challenges influencing industry growth and adoption patterns
- Regional evaluation of North America, Europe, Asia-Pacific, South America, and the Middle East & Africa, including country-level analysis of major research and healthcare markets
- Competitive landscape assessment featuring company rankings, market share analysis, and strategic initiatives undertaken by leading market participants
- Profiles of established companies and emerging players involved in the PBMC market, highlighting their product offerings, business strategies, and recent developments
- Company profiles of major players within the industry, including BioIVT, CGT Global, Charles River Laboratories, Discovery Life Sciences, Lonza, and STEMCELL Technologies
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Market Overview
Chapter 3 Market Dynamics
Chapter 4 Regulatory Landscape
Chapter 5 Emerging Technologies and Developments
Chapter 6 Market Segmentation Analysis
Chapter 7 Competitive Intelligence
Chapter 8 Appendix
Company Profiles
List of Tables
List of Figures
Executive Summary
The global market for peripheral blood mononuclear cells (PBMCs) was valued at $322.2 million in 2025 and, is estimated to reach $353.9 million by 2026 and $577.2 million by 2031, at a compound annual growth rate (CAGR) of 10.3% from 2026 through 2031.Companies Mentioned
- AKADEUM LIFE SCIENCES
- ATCC
- BIOIVT
- BIOLEGEND INC.
- CGT GLOBAL
- CHARLES RIVER LABORATORIES
- CYTIVA
- DISCOVERY LIFE SCIENCES
- IXCELLS BIOTECHNOLOGIES
- LONZA
- MERCK KGAA
- MILTENYI BIOTEC
- PRECISION MEDICINE GROUP LLC
- STEMCELL TECHNOLOGIES
- THERMO FISHER SCIENTIFIC INC.
